XM does not provide services to residents of the United States of America.
G
G

GSK

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

EU regulator backs use of GSK's RSV shot in adults aged 50 to 59

UPDATE 1-EU regulator backs use of GSK's RSV shot in adults aged 50 to 59 Adds background throughout July 26 (Reuters) - The European Union health regulator on Friday recommended expanded use of GSK's GSK.L respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59. Any recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use has to be formally approved by the European Commission, which usually follows the regulator's decision.
G

EU regulator recommends use of GSK's RSV shot in adults aged 50 to 59

EU regulator recommends use of GSK's RSV shot in adults aged 50 to 59 July 26 (Reuters) - The European Union health regulator on Friday recommended expanded use of GSK's GSK.L respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59. Reporting by Prerna Bedi in Bengaluru; Editing by Shounak Dasgupta
G

EMA Says CHMP Recommended Not Granting Marketing Authorisation For Leqembi (Lecanemab)

BRIEF-EMA Says CHMP Recommended Not Granting Marketing Authorisation For Leqembi (Lecanemab) July 26 (Reuters) - Biogen Inc BIIB.O EMA SAYS CHMP EXTENSIONS OF INDICATION FOR 11 MEDICINES THAT ARE ALREADY AUTHORISED IN THE EU INCLUDING AREXVY EMA SAYS CHMP RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR LEQEMBI (LECANEMAB) EMA SAYS CHMP RECOMME
B
G
I

AstraZeneca raises profit outlook on strong medicines demand

UPDATE 5-AstraZeneca raises profit outlook on strong medicines demand Expects 2024 sales and profit to grow by a mid teens percentage Q2 sales of $12.94 billion beat forecast, core EPS $1.98 in line Shares fell as much as 4% Updates shares in paragraph 4 By Pushkala Aripaka and Maggie Fick July 25 (Reuters) - Anglo-Swedish drugmaker AstraZeneca AZN.L raised its full year sales and profit forecast on Thursday after beating analyst expectations for second-quarter revenue on strong demand for its c
A
G
R

GSK Quebec's Committee On Immunization Recommends Use Of RSV Vaccines For Older Adult Populations At Risk Of Severe Outcomes

BRIEF-GSK Quebec's Committee On Immunization Recommends Use Of RSV Vaccines For Older Adult Populations At Risk Of Severe Outcomes July 24 (Reuters) - GSK plc GSK.L : GSK: QUEBEC'S COMMITTEE ON IMMUNIZATION RECOMMENDS USE OF RSV VACCINES FOR OLDER ADULT POPULATIONS AT RISK OF SEVERE OUTCOMES Source text for Eikon: ID:nCNWrtMg6a Further company cove
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.